Using rTMS to treat impulse control disorders in Parkinson's disease
The Effects of High-Frequency Repetitive Transcranial Magnetic Stimulation on Impulse Control Disorders in Parkinson's Disease Patients on Dopamine Replacement Therapy.
NA · West Virginia University · NCT06237868
This study is testing if a treatment called rTMS can help people with Parkinson's disease who struggle with impulse control issues feel more in control of their behaviors.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | West Virginia University (other) |
| Locations | 1 site (Morgantown, West Virginia) |
| Trial ID | NCT06237868 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effects of repetitive transcranial magnetic stimulation (rTMS) on impulse control symptoms in patients with Parkinson's Disease who experience impulse control disorders. Participants will undergo both active rTMS and sham rTMS sessions in a randomized order, followed by neurocognitive tasks and questionnaires to assess changes in behavior and cognitive functions related to impulse control. The trial aims to determine if rTMS can improve impulse control and cognitive behaviors linked to these disorders.
Who should consider this trial
Good fit: Ideal candidates include individuals with a confirmed diagnosis of Parkinson's Disease and clinician-diagnosed impulse control disorders who are on dopamine-replacement therapy.
Not a fit: Patients with a history of seizures, significant cognitive impairment, or major psychiatric illnesses may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly improve impulse control and quality of life for patients with Parkinson's Disease.
How similar studies have performed: While the use of rTMS for impulse control disorders is a novel approach, similar studies have shown promise in treating other neurological and psychiatric conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinician-confirmed diagnosis of PD * Ability to provide informed consent, written and verbal * Clinician-diagnosed impulse control disorder or impulse control behaviors including punding/hobbyism and dopamine dysregulation syndrome * A Beck Depression Inventory (BDI) (Beck et al., 1961) score of 14 or lower * A Montreal Cognitive Assessment (MoCA) (Nasreddine et al., 2005) score of 20 or higher * On dopamine-replacement therapy Exclusion Criteria: * History of seizures or epilepsy * History of brain lesions (such as multiple sclerosis, tumor) reported * History of vascular issues in the brain, such as stroke * History of a moderate to severe traumatic brain injury * Meeting the criteria for a major psychiatric illness such as schizophrenia or depression (BDI score of 14 or higher). * Having significant cognitive impairment (assessed by MoCA, cutoff score of 20) (Nasreddine, et al., 2005) * Having had TMS done in the recent past (within a year) * Pregnancy assessed in female patients * Intracranial metallic objects (except for dental fillings) * Current use of substances or medications known to significantly reduce seizure threshold.
Where this trial is running
Morgantown, West Virginia
- West Virginia University Hospitals — Morgantown, West Virginia, United States (RECRUITING)
Study contacts
- Principal investigator: Mariya V Cherkasova, PhD — West Virginia University
- Study coordinator: Mariya V Cherkasova, PhD
- Email: mariya.cherkasova@mail.wvu.edu
- Phone: 2403673068
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Impulse Control Disorder, Parkinson Disease